CryoPort (NASDAQ:CYRX) Hits New 12-Month High – Here’s What Happened

CryoPort, Inc. (NASDAQ:CYRX) reached a new 52-week high during trading on Thursday . The company traded as high as $14.68 and last traded at $14.6340, with a volume of 36519 shares trading hands. The stock had previously closed at $14.02.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. BTIG Research upped their target price on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Needham & Company LLC increased their target price on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Guggenheim boosted their price target on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, KeyCorp increased their price objective on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.69.

CryoPort Stock Up 3.9%

The stock has a market capitalization of $733.92 million, a price-to-earnings ratio of 10.97 and a beta of 1.75. The company has a 50 day simple moving average of $10.68 and a 200-day simple moving average of $9.77.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The company had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. As a group, sell-side analysts anticipate that CryoPort, Inc. will post -0.74 earnings per share for the current fiscal year.

Insider Buying and Selling at CryoPort

In other CryoPort news, insider Mark W. Sawicki sold 3,235 shares of CryoPort stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider directly owned 103,697 shares of the company’s stock, valued at approximately $829,576. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 59,939 shares of company stock valued at $471,183. Corporate insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYRX. Basepoint Wealth LLC acquired a new stake in CryoPort in the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC increased its holdings in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after acquiring an additional 4,375 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CryoPort during the third quarter worth approximately $53,000. AlphaQuest LLC bought a new position in shares of CryoPort in the 3rd quarter worth $79,000. Finally, Creative Planning bought a new position in shares of CryoPort in the 2nd quarter worth $96,000. Institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.